The impact of CMV reactivation on mortality after chimeric antigen receptor T-cell therapy.

In models adjusted for key confounders of CAR T-cell target and cytokine release syndrome and/or immune effector cell–associated neurotoxicity syndrome grade ≥2, CMV showed a trend toward increased OM, particularly in patients with CMV reactivation ≥150 IU/mL (adjusted hazard ratio, 2.42; 95% CI, 0.69-8.47; P = .17; Figure 2 ), but this did not reach statistical significance.

also in 53,322 other papers

OS was lower among those with previous CMV reactivation, particularly among those with CMV reactivation ≥150 IU/mL, although this did not reach statistical significance ( Figure 1 ).

also in 111,027 other papers